Re: Farmas USA
tampoco es para pedir perdón;) Es una noticia muy importante, aunque esperada.
"The shares have rise 12.57% since it confirmed exclusive talks with J&J on Dec. 21 but are more than 50% higher since takeover speculation first surfaced in late November"
Lo que es interesante es el deal que han hecho. Había un problema y es que Actelion era muy cara para cualquier farma ya que se ha convertido en la biotech mas grande de eruropa. Lo que han hecho es un spin out del R&D y será una nueva compañía de biotech liderada por el actual CEO de Actelion.
Johnson & Johnson (JNJ) said Thursday it will purchase Swiss biotech Actelion Pharmaceuticals (ALIOY) for $30 billion and plans to spin out the company's research and development unit into a separate business.
J&J will pay $280 per share for the Allschwil, Switzerland-based group, which is the Swiss franc equivalent of Sfr280.08 per share, the companies said in a statement. Once the R&D unit is spun out, Actelion shareholders will receive a one-for-one holding in the new company as a dividend. The deal was unanimously approved by both boards, the statement said.